Novavax, Inc. (NVAX)

Novavax Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	440.3	-187.5	-545.06	-657.94	-1,744
Depreciation & Amortization	27.61	48.5	41.23	29.05	12.66
Stock-Based Compensation	36.02	48.15	85.36	130.3	183.63
Other Adjustments	139.14	-44.89	81.35	443.8	136.79
Changes in Inventories	-3.24	12.91	-74.46	-477.8	-8.87
Changes in Accounts Payable	-322.57	-385.63	-378.81	913.4	600.33
Changes in Unearned Revenue	-622.94	67.11	350.87	-1,046	1,326
Changes in Other Operating Activities	61.04	354.09	-274.44	249.17	-183.39
Operating Cash Flow	-244.64	-87.26	-713.97	-415.94	322.95
Capital Expenditures	-5.56	-13.06	-53.77	-89.06	-54.5
Sale of Property, Plant & Equipment	19.65	192.64	-	-	-
Purchases of Intangible Assets	-0.83	-1.58	-5.04	-3.93	-2.99
Purchases of Investments	-445.27	-825.59	-	-	-2.17
Proceeds from Sale of Investments	353.74	443.55	-	-	159.81
Investing Cash Flow	-78.27	-204.04	-58.81	-92.99	100.15
Long-Term Debt Issued	42.61	-	-	175.25	-
Long-Term Debt Repaid	-	-	-325	-	-
Net Long-Term Debt Issued (Repaid)	42.61	-	-325	175.25	-
Issuance of Common Stock	-4.8	264.58	360.4	248.59	589.62
Net Common Stock Issued (Repurchased)	-4.8	264.58	360.4	248.59	589.62
Other Financing Activities	-10.07	-3.99	-30.94	-98.85	-127.91
Financing Cash Flow	27.74	260.58	4.47	324.99	461.71
Effect of Exchange Rate Changes on Cash and Cash Equivalents	5.93	-7.8	3.27	4.52	-5.29
Net Cash Flow	-289.24	-38.52	-765.04	-179.41	879.52
Free Cash Flow	-250.2	-100.32	-767.74	-504.99	268.45
FCF Margin	-22.27%	-14.71%	-78.05%	-25.48%	23.42%
Free Cash Flow Per Share	-1.45	-0.66	-7.62	-6.46	3.61
Levered Free Cash Flow	-382.74	-103.58	-1,259	-903.84	-51.97
Unlevered Free Cash Flow	-410.95	-149.67	-953.77	-1,062	33.94

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q